MedTrace Logo

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

NCT05848765 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 284

Last updated 2026-05-05

No results posted yet for this study

Summary

The aim of the REFRACT clinical trial is to find new therapies with improved outcomes compared to the current standard treatment available, in patients with relapsed or refractory follicular lymphoma. This will be done by comparing patients who have received a new treatment against patients who receive standard treatment based on their response to the treatment received.

Conditions

  • Relapsed Follicular Lymphoma
  • Refractory Follicular Lymphoma

Interventions

DRUG

Epcoritamab

Bispecific antibody

DRUG

Lenalidomide

Immunomodulatory agent

DRUG

Rituximab

Monoclonal antibody

DRUG

Obinutuzumab

Monoclonal antibody

DRUG

Bendamustine

Alkylating agent (chemotherapy drug)

DRUG

Vincristine

Antineoplastic, Vinca Alkaloid

DRUG

Doxorubicin

Anthracycline

DRUG

Cyclophosphamide

Alkylating agent (chemotherapy drug)

DRUG

Prednisone

Corticosteroid

DRUG

Investigation agent 2

The drug used in round 2 is yet to be confirmed, round 2 is estimated to open in Q4 2025 and the record will be updated when the drug has been confirmed

DRUG

Investigation agent 3

The drug used in round 3 is yet to be confirmed, round 3 is estimated to open in Q3 2027 and the record will be updated when the drug has been confirmed

Sponsors & Collaborators

  • Cancer Research UK

    collaborator OTHER

  • Genmab

    collaborator INDUSTRY

  • University of Birmingham

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-04
Primary Completion
2029-05-31
Completion
2031-11-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05848765 on ClinicalTrials.gov